News / Partnerships / Press Releases - May 17, 2024
On 16 May 2024, EUCOPE signed EURORDIS Open Letter #ActRare2024, during the Closing Plenary session of the 12th European Conference on Rare Diseases and Orphan Products (ECRD), organised in Brussels on 15-16 May 2024. The Open Letter is a result of, and informed by, the… read more
News / Partnerships / Press Releases - June 19, 2023
EUCOPE, along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP) The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access… read more
News / Partnerships / Press Releases - March 24, 2023
On March 22, in a workshop in the European Parliament hosted by MEP Weiss, the OD Expert Group presented its Policy Proposals for the revision of the OMP Regulation. Thanks to everyone who participated in the event, whether in-person or remotely . The OD Expert… read more
EUCOPE Resources / Partnerships - March 14, 2023
Sounds of Science Podcast – Episode 14 Trans-Atlantic Innovation : Building bridges between the EU and US life sciences industry With the passing of the Inflation Reduction Act, significant changes are coming for drug pricing and payment in the United States. At the same time,… read more
News / Partnerships / Press Releases - December 8, 2022
A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit. The ‘Rare Disease Moonshot’ is a commitment and collaboration between seven organisations to break down the barriers to finding new treatments and cures… read more
News / Partnerships - August 2, 2022
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) joined the 57 partner organisations that co-signed EURORDIS’ letter calling on the European Commission to take forward the conclusions of the conference for a European Action Plan on Rare Diseases. EUCOPE is a strong champion for a holistic… read more
News / Partnerships - July 27, 2022
EUCOPE has been selected to join the Joint Industrial Cooperation Forum (JICF), a sub-group of the Health Emergency Preparedness and Response Advisory (HERA) Forum. The first meeting of the JICF took place on 13 July where EUCOPE, along with other industrial organizations and national representatives,… read more
News / Partnerships / Partnerships in Focus - June 30, 2022
At EUCOPE, our commitment is to lead and engage in partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and healthcare systems overall. Through our Partnerships in Focus series, we’ll be highlighting different associates that we… read more
News / Partnerships / Press Releases - March 30, 2022
As the EU trade body for small to mid-sized companies that support, invest and produce the innovative medicines and therapies of the future, EUCOPE is happy to welcome five new members to its organisation. AOP Health, Enterome, Flatiron Health, Novo Nordisk and TETEC all became… read more
Member Spotlight / Partnerships - March 30, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In March, we spoke with Krzysztof (Kris) Wojciechowski, Executive Director, EUCAN Public Policy Lead, Organon. Kris joined Organon in… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information